





AMPK REGULATES HER2 AND EGFR IN BREAST CANCER  
 
by 




A dissertation submitted to Johns Hopkins University in conformity with the 









© 2014 Teraneh Z. Jhaveri 
All Rights Reserved 
ii 
Abstract 
The AMP-activated Protein Kinase (AMPK) is a master regulator of cell 
metabolism, controlling fatty acid synthesis, protein synthesis and carbohydrate 
metabolism. Physiological states with increased AMPK activity are associated with 
decreased cancer incidence, leading to interest in AMPK as a potential target for cancer 
therapy and prevention. To explore a possible role of AMPK modulation in breast cancer 
therapy, we investigated how activation of AMPK affects breast cancer cell signaling and 
survival. Initial experiments found that breast cancer cell lines with amplification and 
over-expression of HER2 (BT474, HCC1419, and SKBR3) or EGFR (MDA231 and 
HCC1806) are 2-fold to 5-fold more sensitive to cytotoxic effects of AICAR, a canonical 
pharmacological activator of AMPK, than breast cancer cell lines that lack HER2 or 
EGFR overexpression (MCF7 and DU4475). 
In parallel to this activation of AMPK, we observed dose- and time-dependent 
inhibitory effects on phosphorylation and activity of HER2 and EGFR in these AICAR-
treated, HER2-amplified breast cancer cells, with activation of AMPK and suppression of 
HER2/ EGFR activity preceding commitment to cell death. To further explore how 
AMPK activity affects HER2/ EGFR, we stably transfected HER2-amplified breast 
cancer cells with constitutively active AMPKα and observed that AMPK activated by this 
genetic manipulation also leads to decreased HER2 and EGFR phosphorylation and 
associated downstream signaling as well as reduced cell growth.  
Finally, we found that morin, a flavonoid compound previously found to inhibit 
fatty acid synthesis, also activates AMPK and inhibits HER2 and EGFR signaling in 
parallel, further supporting the link across these pathways. Metformin, another activator 
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of AMPK, also inhibited EGFR phosphorylation in HER2-amplified breast cancer. Our 
results lead us to postulate that AMPK regulates HER2 and EGFR activity in HER2-
amplified breast cancer cells, and activation of AMPK might provide therapeutic benefit 
in such cancers. 
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Chapter 1: Introduction 
1.1 Cancer Background 
In 2002, nearly 25 million people worldwide were estimated to be living with 
cancer [1]. While the most common causes of cancer-related death are due to lung, 
stomach, or liver cancer, breast cancer remains the most prevalent form of cancer in the 
world [2].  
The term cancer does not refer to a single disease, but rather a group of diseases 
that is characterized with some common attributes [3]. Cancer cells are distinguished by 
the following characteristics: the ability to evade cell death, to maintain proliferative 
signaling, to induce angiogenesis, to evade growth suppressors, to metastasize and to 
retain replicative immortality [4]. Tumorigenesis is considered a multistep process, with 
oncogene activation, loss of tumor suppressor activity and induction of aneuploidy all 
important for cancer development [3, 5].  
1.1.1 Cancer Metabolism 
 In the 1920s, Otto Warburg first observed the widespread abnormal features of 
cancer cell metabolism [6, 7]. In the presence of oxygen, normal cells typically rely on 
oxidative phosphorylation for energy production. Contrastingly, in anaerobic conditions, 
cells undergo glycolysis. However, cancer cells undergo “aerobic glycolysis,” which is 
defined as glycolysis in the presence of oxygen, now known as the Warburg Effect [6-8]. 
Compared to oxidative phosphorylation, glycolysis has approximately an 18-fold lower 
ATP production efficiency [4]. To account for this lower level of energy production, 
cancer cells up-regulate glucose transporters and accordingly display a heightened 
dependence on glucose [8-10]. Dependence on aerobic glycolysis has several benefits for 
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cancer cells. First, if the rate of aerobic glycolysis is high enough, ATP production can 
surpass that of oxidative phosphorylation [8]. Second, glycolysis produces intermediate 
compounds needed for biosynthetic pathways [8]. For example, ribose sugars are used for 
nucleotides and glycerol and citrate for lipids [8].  
 Many oncogenes commonly mutated, or activated in cancer, control tumor cell 
metabolism [11]. The PI3K/AKT/mTOR pathway is a highly conserved system that cells 
utilize to respond to growth factors [8, 12]. Activation of the PI3K/AKT/mTOR pathway 
supports increased biosynthesis and increased transport of glucose and other nutrients [8, 
13]. AKT increases glycolysis and lactate production, while mTOR increases protein 
synthesis [8, 14-16]. The RAS oncogene, a GTP-binding protein, also has a role in 
promoting glycolysis [9, 17]. c-Myc, an oncogenic transcription factor, is often 
overexpressed in cancer [9, 17, 18]. c-Myc, thought to be overexpressed in approximately 
70% of human tumors, upregulates the expression of various metabolic genes, including 
pyruvate kinase and lactate dehydrogenase (LDH-A) [17, 18].  
Inhibition of lactate dehydrogenase (LDH-A) has been shown to prevent the 
Warburg Effect and essentially reverts cellular energy production to oxidative 
phosphorylation [19, 20]. Blocking aerobic glycolysis in tumor cells leads to attenuated 
tumor growth, which suggests that aerobic glycolysis is necessary for tumor cell survival 
and growth [9]. Several tumors also demonstrate increased endogenous fatty acid 
synthesis [21-25], and in these tumors, high levels of fatty acid production are necessary 
to fuel membrane production and lipid-based post-translational modifications of proteins 
[21, 25]. Fatty acid synthase (FASN), a 250-270 kDa homodimeric protein, synthesizes 
long chain fatty acids by using acetyl-CoA as a primer, malonyl-CoA as a 2-carbon 
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donor, and NADPH as a reducing equivalent [21, 26, 27]. Acetyl-CoA Carboxylase 1 
(ACC1) and Acetyl-CoA Carboxylase 2 (ACC2) regulate fatty acid synthesis by 
controlling the levels of malonyl-CoA [28]. High levels of FASN have been observed in 
several different types of cancer, including breast, ovary, lung, melanoma, prostate, 
endometrium, colon and thyroid [25, 29]. FASN is expressed at low or undetectable 
levels in most normal adult tissues, with exceptions being adult liver and adipose tissue 
[29]. FASN expression is highest in metastatic tumors, and tumor metastases and 
correlates with decreased survival and disease recurrence [29]. Inhibition of tumor FASN 
in vitro leads to tumor cell cycle arrest and apoptosis [30]. FASN expression has been 
shown to be stimulated by Epidermal Growth Factor Receptor (EGFR) and Human 
Epidermal growth factor Receptor 2 (HER2) signaling [21, 31-34]. In fact, high 
expression of HER2 is correlated with heightened sensitivity to pharmacological 
inhibition of FASN [33, 34].  
1.1.2 Breast Cancer 
 Breast cancer is the most common type of cancer in women in the United States, 
and the second most common cause of death from cancer in women [35]. In 2010, 
approximately 41,000 women died from breast cancer-related conditions [35]. Risk 
factors for breast cancer include: family history, obesity, alcoholism, nulliparity, late age 
of first pregnancy, late menopause, and exposure to radiation [36, 37]. Breast cancer is a 
broad term that covers a heterogeneous group of diseases [38]. Premalignant lesions that 
have increased risk of malignant transformation include atypical ductal hyperplasia and 
hyperplasic alveolar nodules [36]. Earlier, with immunohistochemistry (IHC), scientists 
determined that 3 major subtypes of breast cancer existed: hormone receptor-positive, 
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HER2-positive, and “triple negative” cancers, which lack expression of hormone 
receptors as well as HER2 [38]. Estrogen Receptor (ER) and Progesterone Receptor (PR) 
positive tumors are known to account for approximately 60% of breast cancers. 
Contrastingly, HER2 positive breast cancer accounts for approximately 25% of breast 
cancers [36]. About 15% of breast cancers lack expression of ER, PR, and HER2 and are 
classified as triple negative breast cancer (TNBC) [36]. Compared to other subtypes of 
breast cancer, TNBC is characteristically more aggressive, with an increased likelihood 
of distant recurrence and death [39, 40]. 
Based on molecular profiling, breast cancer can be divided into at least seven 
different biologic subtypes: luminal A, luminal B, luminal C, HER2-positive, basal-like, 
claudin-low, and normal breast-like [38]. Luminal breast cancers are named for their 
similarity to normal luminal breast epithelium [38]. Luminal A tumors, about 40% of all 
breast cancers, have the best prognosis and are characterized by high expression of ER-
related genes, low expression of HER2-related and proliferation-related genes [36]. 
Luminal B tumors are less common and are characterized by lower expression of ER-
related genes, variable expression of HER2-clusters, and higher expression of 
proliferation-related genes [36]. Luminal C is distinguished by its high expression of a 
novel set of genes with unknown function. Luminal B and C tumors have a worse 
relapse-free survival and overall survival, as compared to luminal A tumors [36]. The 
HER2-positive subtype is characterized by high expression of HER2-related and 
proliferation genes [36]. Basal-like tumors are classified based on their similar expression 
pattern to basal epithelial cells. These tumors are ER/PR and HER2-negative (triple 
negative) and display wide genomic instability [36]. BRCA1 mutations are strongly 
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associated with basal-like breast cancer [36]. Basal-like breast cancer is also 
characterized by high expression of EGFR, p-cadherin, smooth muscle actin, c-kit, and 
cytokeratins 5, 6, 14, and 17 [36]. The claudin-low subtype is characterized by low 
expression of luminal differentiation markers, and high expression of epithelial-to-
mesenchymal transition markers, immune response genes and cancer stem cell-like 
features [36]. Most claudin-low tumors tend to be HER2 and ER/PR negative (triple 
negative). Normal breast-like tumors cannot be characterized into either of the other 
subtypes. Normal breast-like tumors demonstrate high expression of genes known to be 
expressed in adipose tissue, as well as high expression of basal epithelial genes [36].  
1.2 ErbB Family 
 HER2, an oncogene important in many breast cancers, is a member of the ErbB 
family of receptor tyrosine kinases. The ErbB family is composed of 4 homologous 
proteins: EGFR (HER1), HER2, HER3, and HER4. EGFR, HER2 and HER3 have all 
been implicated in promoting tumorigenesis [37]. As receptor tyrosine kinases (RTK), 
these transmembrane proteins influence cell growth, differentiation, and survival [37]. 
RTKs contain 3 domains: an extracellular domain important for ligand binding, a 
transmembrane domain that anchors the protein on the cell membrane, and an 
intracellular domain that contains the kinase segment of the protein [37]. Ligand binding 
induces hetero- or homodimerization of the ErbB family of kinases, followed by 
autophosphorylation of key activating residues on the intracellular domain of the RTK 
[37, 41]. Autophosphorylation of the RTK leads to recruitment of signaling molecules 
and activation of a variety of downstream signaling pathways [41].  
1.2.1 HER2 
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 HER2 is an 185 kDa transmembrane oncoprotein that occurs in 20-25% of all 
breast cancers [41]. HER2 overexpression and/or amplification have also been observed 
in colon, bladder, ovarian, endometrial, lung, uterine cervix, head and neck, gastric and 
esophageal carcinomas [42-48]. Unlike the other ErbB family members, HER2 is an 
“orphan receptor,” meaning it has no known ligand [37, 41]. HER2 is the preferred 
binding partner for the other members of the ErbB family. HER2 is considered 
“constitutively active,” as it requires no binding of a ligand to be active [41]. HER2-
containing heterodimers evade normal inactivation processes by internalizing relatively 
slowly and by returning to the cell surface- thereby avoiding the process of degradation 
[49]. HER2 overexpression is associated with anchorage-independent cancer cell growth, 
increased cell migration, increased angiogenesis and increased cell proliferation [49]. 
HER2 downstream signaling is important for cancer growth and development. In cancer, 
the Ras/Raf/mitogen-activated protein kinase (MAPK) and the phosphoinositide 3-kinase 
(PI3K)/Akt pathways are two important signaling cascades that promote cancer growth 
and survival downstream of HER2 signaling [41, 49].  
 Current therapeutic options for patients with HER2-positive tumors include 
trastuzumab (Herceptin®), lapatinib (Tykerb®), and pertuzumab (Perjeta®) [41]. 
Trastuzumab, a humanized monoclonal antibody that binds to HER2, was approved for 
use in metastatic breast cancer in 1998 and early stage breast cancer in 2008 [41]. Recent 
clinical trials have been exploring the use of trastuzumab in HER2-positive gastric or 
gastric-esophageal carcinomas [50]. Although the exact mechanism of action is unknown, 
trastuzumab binds to the juxtamembrane portion of the extracellular domain of HER2 
[41]. It has been proposed that trastuzumab may induce apoptosis, inhibit angiogenesis, 
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inhibit cell signaling and cause antibody-dependent cell cytotoxicity [36, 51]. A phase III 
study of trastuzumab plus various chemotherapy regimens showed a significant 
improvement in overall survival (25.1 vs. 20.3 months) and overall response rate (50 vs. 
32%) in breast cancer patients [52]. However, approximately half of HER2-positive 
breast cancer patients display resistance to trastuzumab and of the patients who respond, 
most end up with progressive disease while on trastuzumab therapy [41, 51]. In the 
adjuvant setting, addition of trastuzumab to the standard chemotherapy regimen reduced 
rates of reoccurrence by over 50% [53]. Trastuzumab resistance has been correlated to 
activation of both the PI3K and the Insulin-like growth factor receptor (IGF-IR) signaling 
pathways [54-56]. High levels of ErbB family ligands (growth factors) can also drive 
resistance to RTK inhibitors [57]. Lapatinib, a small molecule inhibitor of both EGFR 
and HER2 tyrosine kinase activity, was approved for use in HER2-positive breast cancer 
in 2007 [41]. Phase I studies of lapatinib have demonstrated response both as a single 
agent (6%) and in combination with trastuzumab (26%) [37, 58]. Pertuzumab, a 
recombinant humanized monoclonal antibody, functions by disrupting HER2 
dimerization [41]. Pertuzumab was approved by the FDA in 2012 for patients with 
metastatic HER2-positive breast cancer [59]. Patients receiving pertuzumab in 
combination with docetaxel and trastuzumab displayed increased progression-free 
survival as compared to the control group (18.5 vs. 12.4 months) [59]. Similar to 
trastuzumab, pertuzumab stimulates antibody-dependent, cell-mediated cytotoxicity [60]. 
Contrastingly, pertuzumab binds to HER2 and prevents its dimerization with HER3, 
thereby preventing HER2 downstream signaling [41].  
1.2.2 EGFR 
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EGFR – also known as HER1, is a 170 kDa protein that overexpressed or 
overactive in a variety of solid tumor types, including about 20% of breast cancer [56, 
61]. EGFR overexpression is more often found in triple negative breast cancer and is 
associated with a more aggressive phenotype [56]. However, EGFR inhibition to date has 
relatively limited clinical benefit in breast cancer patients [56, 62]. Elevated EGFR levels 
have a strong correlation with poor prognosis in head and neck, glioma, cervical, ovarian, 
esophageal and bladder cancers [62]. In gastric, breast, endometrial, and colorectal 
cancers, EGFR overexpression has modest prognostic implications, while in non-small 
cell lung carcinoma, EGFR overexpression seldom has prognostic implications [62].  
Eleven ligands are known to bind to the ErbB family of tyrosine kinase receptors 
[61]. Ligands that specifically bind to EGFR are: epidermal growth factor (EGF), 
transforming growth factor-α (TGF-α), amphiregulin, and epigen [61]. Ligands that bind 
to both EGFR and HER4 include: betacellulin, heparin-binding EGF, and epiregulin [61]. 
Neuregulin 1 (NRG1) and 2 (NRG 2) bind both HER3 and HER4, while NRG3 and 
NRG4 only bind HER4 [61].  
Mutations of EGFR are quite commonly seen in cancer. EGFR VIII is a deletion 
mutation of amino acids 30-297, resulting in a EGFR protein that is constitutively 
activated without requiring ligand binding [61]. EGFR VIII is reported to occur in 30-
50% of glioblastomas, 21% of squamous head and neck carcinomas, 5% of squamous 
lung carcinomas, and 5% of breast carcinomas [61, 62]. EGFR VIII is associated with 
poor survival in glioblastoma patients; median survival of patients with EGFR VIII 
mutation is 45 weeks, as compared to 85 weeks in the non-EGFR VIII patient population 
[63]. Other mutations of EGFR include mutations that involve the kinase domain. 
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Mutations in exon 18, the nucleotide binding loop region, account for 5% of EGFR 
mutations, while mutations in exon 19, account for 45% of EGFR mutations [62]. The 
L858R substitution in exon 21 accounts for another 40-45% of EGFR mutations. EGFR 
exon 20 mutations account for up to 4% of all EGFR mutations, with T790M comprising 
about 50% of exon 20 mutations [62]. The T790M mutation is correlated to increased 
resistance to tyrosine kinase inhibitors (TKI) [62]. About 60% of patients with acquired 
resistance to EGFR TKI have tumors that are characterized with the T790M mutation 
[64]. While mutations of EGFR are rare in breast cancer, the frequency of activating 
mutations of EGFR in hereditary breast cancer is greater than in spontaneous breast 
cancer [65].  
 While EGFR inhibitors have been tested in clinical trials for the treatment of 
breast cancer, the results of such trials have not been encouraging [65]. For example, 
clinical trials with the tyrosine kinase inhibitors gefitinib and erlotinib failed to 
demonstrate an improved response rate. However, this poor outcome may relate to the 
fact that these studies did not select patients that had established EGFR expression [65]. 
Furthermore, a phase II clinical trial determined the overall response rate of cisplatin with 
cetuximab (a chimeric EGFR-targeting monoclonal antibody) was doubled to that of 
cisplatin alone (20 vs. 10.3%) [65]. Panitumumab, a humanized monoclonal antibody 
specific to EGFR, demonstrated an 80% overall response rate in combination with 5-
fluorouracil, epidoxorubicin (epirubicin), and cyclophosphamide followed by docetaxel 
for neoadjuvant therapy in TNBC patients [65]. As antibodies, cetuximab and 
panitumumab function by blocking the binding of ligands to the extracellular domain of 
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EGFR, promoting receptor internalization (and subsequent degradation), and mediating 
antibody- and complement-mediated cytotoxicity [64].  
1.3 AMP-activated Protein Kinase (AMPK) 
 Cellular energy balance is vital part of all cell biological processes, including cell 
growth, division and movement. In cells, ATP levels are maintained in the low millimolar 
range, which indicate a delicate balance between energy-consumption processes and 
energy-producing processes [66]. AMP-activated protein kinase (AMPK) is a highly 
conserved cellular sensor of AMP and ADP levels [66-68]. AMPK orthologues have 
been found in Arabidopsis, Saccharomyces cerevisiae, Dictyostelium, Caenorhabditis 
elegans, Drosophila, and Physcomitrella patens [67].  
1.3.1 AMPK Structure and Activation 
 AMPK is a heterotrimeric serine/threonine kinase composed of α, β, and γ 
subunits [66-68]. In humans, two isoforms of the α subunit (α1 and α2), two isoforms of 
the β subunit (β1 and β2), and three isoforms of the γ subunit (γ1, γ2, and γ3) exist [66]. 
Twelve different combinations of AMPK trimers can exist. Some AMPK combinations 
are not found in specific tissues and each trimer combination displays a distinct spectrum 
of biochemical properties [66]. The α1 isoform is predominantly found in white adipose 
tissue, blood cells, smooth muscle, endothelial cells and nerve [66], whereas α2 is the 
predominant isoform in muscle and heart [66]. While AMPK proteins are generally found 
in the cytoplasm, several AMPK subunits have also been found in the nucleus (α2, β2, γ1, 
and γ3), suggesting a possible role in the regulation of gene expression [66].  
The α subunit of AMPK represents the catalytic region of the protein, containing 
the key threonine 172 residue, whose phosphorylation is required for complete AMPK 
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enzymatic activity [66]. The α subunit partners with the β and γ subunits through it C-
terminal domain [66]. The β subunits contain a carbohydrate-binding domain, which 
allows AMPK to interact with glycogen particles. The γ subunit contains four tandem 
repeats known as cystathionine β-synthase (CBS) motifs, which allows AMPK to bind 
two AMP, ADP, or ATP molecules in a mutually exclusive way, and a third AMP 
molecule in a non-exchangeable way [66, 69]. While binding of ATP to AMPK 
maintains the kinase in a low activity state, binding of AMP to AMPK leads to a fivefold 
activation of the enzyme [66]. AMP binding also makes AMPK an inferior substrate for α 
subunit threonine 172 phosphatase, which allows for elevated levels of phosphorylated 
AMPK α 172 [66, 68, 69]. The allosteric effects of AMP binding also favor AMPK α 
phosphorylation by upstream AMPK-activating kinases. AMP binding to AMPK and 
phosphorylation of AMPKα at threonine 172 result in a greater than 1,000-fold activation 
of AMPK [66, 68].  
In humans, six different point mutations in the gene encoding the γ2 subunit are 
responsible for the Wolff-Parkinson-White syndrome (WPWS), a hereditary heart disease 
that is usually associated with hypertrophic cardiomyopathy (HCM) [68]. The 
mechanism behind how these mutations cause WPWS and HCM is currently unknown, 
but preliminary evidence suggests that these mutations work to increase the basal activity 
of AMPK [68].  
 Identified upstream kinases that phosphorylate AMPK α 172 are: 1) liver kinase 
B1 (LKB1), calcium and calmodulin-dependent protein kinase kinase (CaMKK), 2) TGF-
β-activating kinase (TAK1), and 3) the protein of the ataxia-telangiectasia mutated 
(ATM) gene [66, 70]. In hypothalamic neurons, T cells and endothelial cells, CaMKK 
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seems to play a role in the activation of AMPK [71]. LKB1, also known as 
serine/threonine kinase 11 (STK11) is ubiquitously expressed and is the main kinase 
required for AMPK activation [70]. LKB1 functions in a heterotrimeric complex with 
Sterile-20-Related Adaptor (STRAD) and Mouse protein 25 (Mo25) [66]. Most evidence 
supports the concept that LKB1 is a constitutively active kinase [66]. LKB1 is the main 
upstream kinase for the 13 members of the AMPK-related kinase family [66]. LKB1 is a 
known tumor suppressor and loss of function mutations result in Peutz-Jeghers syndrome 
[66, 70], which is characterized by multiple hamartomatous polyps in the gastrointestinal 
tract and a heightened risk of gastrointestinal adenocarcinomas [70]. Somatic mutations 
of LKB1 have been observed in several types of cancer, including: lung adenocarcinomas 
(34%), cervical carcinomas (20%), and squamous cell carcinomas (19%) [70]. Low 
expression of LKB1 has been reported in clear cell renal carcinoma, resulting in lower 
AMPK activity and a growth advantage of cancer cells in vitro and in vivo [72]. 
Complete ablation of LKB1 in the mouse model leads to embryonic lethality, but 
heterozygous deletion increases the incidence of spontaneous tumors in the intestine and 
stomach [70]. A hypomorphic mutation that decreases LKB1 activity rapidly increases 
tumor development in PTEN
+/-
 mice; however, treatment with AMPK pharmacological 
activators significantly delay tumor development [70]. As LKB1 is frequently co-mutated 
with KRAS in non-small cell lung cancer (NSCLC), a mouse model bearing a 
conditionally activated allele of Kras and a conditionally inactivated allele of Lkb1 had a 
phenotype of increased tumor incidence, metastasis and acceleration of death [73]. LKB1 
is reportedly phosphorylated by ERK and Rsk, which inhibit LKB1 binding and 
phosphorylation of AMPK [74].  
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1.3.2 AMPK Activators 
 As a cellular energy sensor, AMPK is activated by metabolic stresses that either 
inhibit ATP synthesis or accelerate ATP consumption [69]. AMPK can be activated by 
metabolic stresses that inhibit ATP production via oxidative phosphorylation, such as 
arsenite, oligomycin, antimycin A, azide, dinitrophenol, hydrogen peroxide, hypoxia or 
ischemia [75-80]. AMPK is also activated in skeletal muscle in response to exercise 
(contraction of muscle fibers) [81-83]. AMPK is also regulated by physiological 
variations in glucose; most notably, AMPK is activated in conditions of low glucose [84, 
85]. In humans, activation of AMPK in the hypothalamus leads to increased feeding 
behavior, indicating a conserved role of AMPK in maintaining energy homeostasis [86, 
87]. The gut hormone ghrelin and the cannabinoids have been reported to activate AMPK 
in the hypothalamus [87, 88]. Leptin, an adipokine (cytokine released by adipocytes), 
represents a signal that food stores are adequate [89]. Leptin was reported to activate 
AMPK in the mouse muscle, yet inhibit AMPK activity in the hypothalamus [86, 90]. 
AMPK is also activated by adiponectin (ACRP30) in skeletal muscle [91]. Liver AMPK 
is necessary for adiponectin-dependent lowering of blood glucose [92]. 
 Pharmacological activators of AMPK are commonly utilized for research 
purposes. The canonical activator of AMPK, AICAR (5-aminoimidazole-4-carboxamide-
1-β-D-ribofuranoside), is an adenosine analog that is taken up into the cell by adenosine 
transporters [75, 93] and then converted by adenosine kinase to the phosphorylated 
nucleotide ZMP (AICAR monophosphate) [67]. ZMP mimics AMP, binding directly to 
the AMPK γ subunit and activating AMPK directly [67]. AICAR is not approved for use 
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in the clinic; however, a clinical trial examining the potential benefit of AICAR for 
treatment of chronic lymphocytic leukemia (CLL) is currently underway [94].  
Metformin and other biguanides (including phenformin) activate AMPK through 
an indirect mechanism, by blocking ATP production through the inhibition of 
mitochondrial Complex I of the respiratory chain [95-97]. Metformin, commonly used to 
treat type 2 diabetes, increases insulin sensitivity and improves glycemic control [98-
100]. Early reports indicated that type 2 diabetic patients receiving metformin had a 30% 
decrease in the incidence of cancer, as compared to patients not receiving metformin 
[101, 102]. Each five-year metformin treatment period was correlated to a 0.73 reduction 
in cancer-related death [103]. Metformin and thiazolidinediones, both used for the 
treatment of diabetes, activate AMPK. A study analyzing the survival of diabetic women 
with HER2+ cancer determined that metformin or thiazolidinediones use was correlated 
with decreased breast cancer-related mortality, indicating a link between AMPK 
activation and inhibition of breast cancer growth [104]. Metformin use in diabetic breast 
cancer patients was associated with 24% change in the pathologic complete response 
(pCR) rate, while diabetic cancer patients not using metformin had a 8% pCR rate [105]. 
Metformin treatment in breast cancer cell lines has been associated with cell cycle arrest, 
reduction in cyclin D1 and E2F1 [106].  
Pemetrexed, a chemotherapeutic drug used for mesothelioma and NSCLC 
treatment, is another agent that might act in part by activating AMPK. Pemetrexed is well 
known to inhibit thymidylate synthase, and pemetrexed also inhibits AICART 
(aminoimidazolecarboxamide ribonucleotide formyltransferase) [107], a folate-dependent 
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enzyme of purine biosynthesis, which results in increased intracellular ZMP and 
activation of AMPK [107]. 
A number of naturally occurring compounds have been reported to activate 
AMPK. For example, resveratrol, a polyphenol, inhibits F1F0 mitochondrial ATP 
synthase, which results in an increased AMP to ATP ratio, leading to activation of 
AMPK [96]. Resveratrol treatment in mice increases metabolic activity, insulin 
sensitivity, glucose tolerance, mitochondrial biogenesis, and physical endurance [108, 
109]. In AMPKα1
-/-
 knockout mice, resveratrol treatment failed to improve metabolic 
activity, insulin sensitivity, glucose tolerance, mitochondrial biogenesis, and physical 
endurance [108, 109], consistent with this activity being due to activation of AMPK. 
Resveratrol increases the NAD-to-NADH ratio in an AMPK-dependent manner, which is 
proposed to explain how resveratrol activates Sirt1 [108, 110]. Polyphenol treatment, 
including resveratrol, apigenin, and S17834, in HepG2 cells not only activated AMPK 
with 200 fold the potency of metformin, but also decreased lipid accumulation in cells 
exposed to high levels of glucose [111]. Resveratrol has also been reported to directly 
inhibit cAMP-specific phosphodiesterases (PDE) [112]. Resveratrol treatment in chronic 
myelogenous leukemia (CML) not only activates AMPK, leading to downstream 
inhibition of the mTOR pathway, but also induces autophagy through JNK-dependent 
accumulation of p62 [113].  
Several flavonoid compounds have also been reported to activate AMPK [114-
120]. The flavonoids genistein, kaempfrol, quercetin, and fisetin have been reported to 
activate AMPK, although the mechanism of AMPK activation has yet to be elucidated.  
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Morin, [2-(2′,4′-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one], a 
flavonoid identified in fruits, vegetables, tea and wine [121], has not previously been 
reported to activate AMPK. Morin is a yellow pigment isolated from the plants of the 
Moraceae family [122] that has been reported to have beneficial medicinal properties, 
however. For example, morin has been reported to have anti-inflammatory, anti-
neoplastic, and cardioprotective activities [123, 124], and studies have suggested that 
adequate intake of flavonoid-rich foods (although not specifically morin) may reduce the 
risk of cancer and coronary heart disease [121, 125, 126]. In laboratory experiments, 
morin has been shown to have deleterious effects on breast cancer cell lines through 
disruption of the mitochondrial membrane potential [121]. Morin has been reported to 
inhibit the growth of COLO205 cells in nude mice as well as protect against chemically 
induced rat tongue carcinogenesis [127, 128]. Additionally, morin has been attributed 
with suppressing the proliferation of squamous cell carcinoma, leukemia, and colon 
cancer cell lines [129-131]. Morin has been shown to induce p21 and activate caspases, 
suppress AKT activation, induce stress kinase activation, abolish peroxisome 
proliferator-activated receptor activity, inhibit P-glycoprotein, inhibit lipooxygenase-1, 
suppress nuclear factor-κB (NFκB) activity, suppress inducible nitric oxide synthase and 
cyclooxygenase-2 (COX-2) expression and inhibit the release of inflammatory cytokines, 
such as IL-6, IL-8 and tumor necrosis factor (TNF) [127, 128, 131-136]. While morin has 
not yet reported to activate AMPK, morin has been reported to inhibit fatty acid synthase 
(FASN) at an in vitro IC50 value of 2.33 μM [137]. Given that AMPK activation also 
leads to inhibition of FASN (through inhibition of ACC), we explored the possibility that 
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morin-based inhibition of FASN may function through the activation of AMPK in our 
work described below. 
1.3.3 AMPK Downstream Targets 
1.3.3.1 Metabolism 
A major target of AMPK activity is fatty acid and cholesterol synthesis. AMPK 
was first identified as a kinase that phosphorylates and inhibits acetyl CoA carboxylase 
(ACC) and HMG-CoA reductase, both rate-limiting enzymes in the synthesis of fatty 
acid and cholesterol, respectively [70]. HMG-CoA reductase inhibitors, statins, have been 
proposed to prevent cancer in experimental models [138, 139]. As mentioned earlier, 
FASN and ACC are often highly expressed in several types of cancer [25, 140]. Increased 
levels of FASN and ACC are attributed to increased expression of the transcription 
factors, sterol regulatory element binding protein 1 and 2 (SREBP-1 and SREBP-2) 
[141]. Inhibition of FASN in human ovarian cancer cells leads to activation of AMPK, 
followed by induction of cytotoxicity. Compound C, a pharmacological inhibitor of 
AMPK, reportedly prevents the cytotoxic effect of FASN inhibition, suggesting that 
AMPK activation is necessary for the induction of cytotoxicity by FASN inhibitors [142]. 
AMPK also stimulates fatty acid uptake through the translocation of the fatty acid 
transporter FAT/CD36 [143]. AMPK functions to inhibit triglyceride and phospholipid 
synthesis by inactivating glycerol phosphate acyl transferase, glycogen synthesis by 
phosphorylation of glycogen synthase, and ribosomal RNA synthesis by phosphorylation 
of the RNA polymerase I transcription factor TIF-1A (RRN3) [144-146]. 
AMPK also regulates glucose uptake through the activation of the glucose 
transporters, GLUT1 and GLUT4 [147, 148]. AMPK phosphorylates histone deacetylase-
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5, which increases GLUT4 transcription [149], and AMPK stimulates glycolysis by 
phosphorylating two of the four isoforms of 6-phosphofructo-2-kinase, the enzyme 
responsible for the synthesis of the glycolytic activator fructose-2,6-bisphosphate [76, 
150]. AMPK also represses transcription of glucose-6-phosphatase and 
phosphoenolpyruvate carboxykinase mRNAs, thereby inhibiting gluconeogenesis [144, 
151]. 
In addition to these effects on carbohydrate metabolism, AMPK also regulates 
protein synthesis through a variety of downstream effectors. For example, AMPK inhibits 
elongation of translation by promoting phosphorylation of eukaryotic elongation factor 2 
(eEF2) [152, 153]. Another important target of AMPK is the mammalian target of 
rapamycin (mTOR) complex-1 (mTORC1); AMPK directly phosphorylates and activates 
the mTORC1 upstream regulator Tuberous Sclerosis Complex (TSC2) and this activation 
of TSC2 leads to inhibition of mTORC1. Additionally, AMPK phosphorylates the 
mTORC1 subunit Raptor, which also functions to inhibit mTORC1 function [154, 155]. 
As mTORC1 positively regulates cell growth and proliferation by promoting protein, 
lipid and organelle biosynthesis, AMPK-based inhibition of mTORC1 effectively 
downregulates several anabolic pathways required for cell growth [156]. 
1.3.3.2 Regulation of Mitochondrial Biogenesis and Autophagy 
 Chronic activation of AMPK in the muscle of mice leads to the up-regulation of 
nuclear-encoded mitochondrial genes and improves the endurance of mice in treadmill 
running tests [157]. This interesting consequence of AMPK activation is proposed to be 
due to upregulation of mitochondrial function by enhancing the transcription of 
peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC-1α), a 
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transcription factor responsible for the biogenesis of new mitochondria as well as the 
expression of nuclear-encoded mitochondrial genes [144, 158].  
 AMPK also has a direct effect on the process of autophagy, the process of 
recycling cytoplasmic components through engulfment by autophagic vacuoles that then 
fuse with lysosomes [144]. Autophagy is particularly important under conditions of 
nutrient deprivation as a means to produce catabolic fuels and recycle amino acids for the 
production of important proteins [144]. The unc-51 like kinase 1 and 2 (ULK1 and 
ULK2) isoforms initiate the autophagy cascade [144], and ULK1 and ULK2 were found 
to form a stable complex with AMPK, allowing AMPK to phosphorylate ULK1 at 
several sites [159-161]. Cells lacking ULK1 or AMPK displayed a marked increase of 
accumulated mitochondria [160]. In cells where the endogenous ULK1 was replaced by a 
mutant in which the four serine residues identified as AMPK sites were mutated to 
alanine, starvation induced the accumulation of abnormal mitochondria [160]. Notably, 
without AMPK or ULK1 function, fewer cells survived starvation conditions [160]. 
1.3.3.3 Cell Cycle Regulation 
Activation of AMPK in cultured tumor cells causes a G1–S-phase cell cycle arrest 





[144, 162-164]. AMPK is proposed to phosphorylate 
p53 directly at serine 15 and p27
Kip1 
at threonine 198 [163, 164]. AMPK activation also 
reduces the cytoplasmic to nuclear ratio of the RNA-binding protein HuR, reducing its 
ability to stabilize mRNAs involved in cell cycle regulation [75]. Increased AMPK 
activity also appears to promote cell senescence [75].  
1.3.3.4 Transcriptional Targets 
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 AMPK has been reported to phosphorylate and regulate a number of transcription 
factors and coactivators, including the acetyltransferase p300, some histone deacetylases, 
and histones [67]. Histone H2B serine 36 is proposed to be an AMPK phosphorylation 
site, however, this site does not conform well to the AMPK consensus sequence [67]. 
AMPK has also been linked to regulation of the circadian clock, by phosphorylation of 
Cry1 serine 71, which targets the protein for ubiquitin-mediated degradation [165]. 
AMPK also phosphorylates proteins of the CRTC (cyclic AMP-regulated transcriptional 
co-activators) family, which are transcriptional co-activators for CREB (cAMP response 
element binding protein) [67]. Additional targets of AMPK include the nuclear receptors 
HNF4α (hepatocyte nuclear factor-4 alpha), TR4 (testicular receptor 4), and the zinc-
finger protein AREBP (AICAR response element binding protein) [166-168]. The class 
IIa family of histone deacetylases (HDACs), which represent yet another group of AMPK 
targets [67], are inhibited by AMPK-mediated phosphorylation [67]. In certain cell types, 
AMPK is reported to stimulate a set of FOXO-dependent target genes under stress 
conditions through the direct phosphorylation of FOXO3 and FOXO4 [169]. In addition 
to phosphorylating transcriptional regulators, AMPK appears to regulate the activity of 
the deacetylase SIRT1 through effects on NAD+ levels [170, 171]. 
1.3.3.5 Cell Polarity 
 Embryos lacking LKB1 or AMPK display similar defects in epithelial cell 
polarity during development [172]. LKB1 appears necessary for the establishment of cell 
polarity under all conditions, while AMPK is only necessary for the establishment of cell 
polarity under starvation conditions [173]. Although AMPK-null mice survive and do not 
seem to have similar effects as Drosophila in cell polarity, there still remains evidence 
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that the LKB1-AMPK pathway is important in maintaining epithelial cell polarity in 
mammals [144]. Experiments using the intestinal epithelial cancer cell line LS174T, 
which does not express LKB1, found that re-expression of LKB1 and STRAD caused a 
rapid remodeling of the actin cytoskeleton and a reformation of an apical brush border 
membrane [174]. Other experiments using Madin Darby canine kidney (MDCK) 
epithelial cells found that the removal of Ca
2+
 from the medium results in a loss of 
polarity and of tight junctions, while restoration of Ca
2+
 in the media re-establishes both 
polarity and tight junctions, concomitant with activation of AMPK [175]. In Vero cells, 
AMPK was shown to phosphorylate the microtubule plus-end protein CLIP-170 
(Cytoplasmic linker protein 170). Mutation of the AMPK phosphorylation site on CLIP-
170 resulted in slower microtubule assembly [176]. AMPK also may play a role in 
polarizing neurons through the control of phosphatidylinositol 3-kinase (PI3K) 
localization. By phosphorylating kinesin light chain 2 (KLC2), AMPK was shown to 
inhibit axonal growth by preventing PI3K localization to the axonal tip [177]. 
1.3.3.6 AMPK and Cancer 
 The discovery that LKB1, a known tumor suppressor, was the upstream activating 
kinase to AMPK provided a key link between AMPK and cancer [178]. AMPK appears 
to be the main mediator of the LKB1 tumor suppressor effects, as of the AMPK and 
AMPK-related kinases, only AMPK is known to cause inhibition of cell growth and 
biosynthesis [144]. The observation that diabetics treated with metformin had a lower 
incidence of cancer than diabetics not treated with metformin further established the idea 
that AMPK activation may have anti-tumor effects [101]. Furthermore, treatment of a 
tumor-prone mouse model with three different activators of AMPK: metformin, 
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phenformin, or A-769662 (a direct activator of AMPK developed by Abbot) significantly 
delayed tumor development [179, 180].  
Other evidence also suggests that AMPK signaling is important in the 
development of specific types of cancers. In primary human breast cancer, reduced 
AMPK signaling was observed in 89.4% and 91.9% in two cohorts of patients [181]. A 
role for reduced AMPK signaling in melanoma has been suggested to occur through the 
mutated form of the proto-oncogene B-Raf (V600E, causing constitutive activation) [74], 
which occurs in up to 50% of all malignant melanomas [144]. In melanoma cell lines 
with this mutation, LKB1 was found to be phosphorylated at two C-terminal sites by B-
Raf downstream kinases [74], and it is highly possible that these phosphorylations on 
LKB1 inhibit LKB1-dependent phosphorylation and activation of AMPK [74]. Akt-
mediated phosphorylation of AMPK at α1 subunit serine 485 (α2 serine 491) has also 
been proposed to inhibit LKB1-mediated phosphorylation at α subunit threonine 172, 
thereby inhibiting AMPK activation in cancer [182]. Furthermore, mRNA levels of 
AMPKα2 inversely correlate with clinical prognosis in ovarian and breast cancers, and 
are diminished in cancer cells by the activation of the PI3K pathway [183]. In conclusion, 
while cancer cells appear to need AMPK for survival in conditions of deprivation, cancer 
cells must also maintain a tight control over AMPK activation [70]. Activation of AMPK 
must be strictly regulated to prevent inhibition of cellular growth pathways. Therefore, 
AMPK presents an attractive therapeutic target for the treatment of cancer [70]. 
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Chapter 2: Experimental Procedures 
Materials 
Anti- phospho-AMPKα (172), phospho-HER2 (1221/1222, 1248, 1196), 
phospho-HER2/phospho-EGFR (1248/1173), phospho-HER3 (1289), phospho-EGFR 
(1068, 1046/1047, 1045), phospho-ACC (79), phospho-AMPK substrates 
(LXRXXpS/pT), AMPKα, AMPKβ1/2, ACC, PARP, HER2, EGFR, HER3, LKB1, 
FASN and Myc-tag primary antibodies were purchased from Cell Signaling Technology. 
Anti-rabbit and anti-mouse secondary antibodies were also purchased from Cell 
Signaling Technology. Anti-phospho-EGFR (1142) was purchased from ECM 
Biosciences. Anti-Actin antibody was purchased from Sigma-Aldrich. 5-Amino-4-
imidazole carboxamide riboside (AICAR), a pharmacological activator of AMPK, was 
purchased from Toronto Research Chemicals (Toronto, ON, Canada). AICAR was 
dissolved in dimethyl sulfoxide (DMSO) to make a 500mM stock concentration. Morin 
hydrate was purchased from Sigma-Aldrich and dissolved in DMSO to make a 50mM 
stock solution. C75 was purchased from Sigma-Aldrich. 2-Deoxy-D-glucose (Sigma-
Aldrich) was dissolved in Phosphate Buffered Saline (PBS) to a stock solution of 2M. 2,5 
dideoxyadenosine (Sigma-Aldrich) and lapatinib ditosylate (LC Laboratories) were 
dissolved in DMSO. Metformin hydrochloride (Sigma-Aldrich) was dissolved in PBS to 
make a 500mM stock solution. Epidermal growth factor (EGF) (Sigma-Aldrich) was 
prepared in a stock concentration of 100μg/ml in purified water. Compound C in solution 
was obtained from Calbiochem. G418 was obtained from Invitrogen. 0.25% Trypsin-
Ethylenediaminetetraacetic acid (EDTA), Hank’s balanced salt solution (HBSS) and PBS 
were purchased from Gibco. Control, AMPKα1/2, AMPKβ1, and AMPKβ2 siRNAs were 
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purchased from Santa Cruz Biotechnology. All siRNA transfections were conducted in 
triplicate over a period of 72 hours using RNAiMax (Invitrogen) according to the 
manufacturer’s recommendation.   
Cell Culture 
Human cancer cell lines HCC1937, DU4475, BT549, HCC1806, HCC1954, 
MDA231, HCC1419, H157, H1975, HCC827, SKMES1, U1752, Calu6 were cultured in 
RPMI media (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco). BT474 
was grown in DMEM/F12 media (Gibco) supplemented with 10% FBS. SUM102 and 
SUM159 cell lines were grown in Ham’s F12 media (Gibco) with 5% FBS supplemented 
with 5μg/ml insulin (Gibco) and 1μg/ml hydrocortisone (Sigma). MCF7 and Hs578t cell 
lines were cultured in DMEM media (Gibco) with 10% FBS. SKBR3 was grown in 
McCoy’s media (Gibco) with 10% FBS. MDA468 and MDAMB175VII were grown in 
L15 media (Gibco) with 10% FBS in 100% atmosphere. MCF10A was grown in 
DMEM/F12 media supplemented with 5% horse serum (Gibco), 0.5μg/ml 
hydrocortisone, 10μg/ml insulin, 20ng/ml EGF, 0.1μg/ml cholera toxin (Sigma) and 
100μg/ml each of penicillin and streptomycin (Gibco). All cell lines were cultured at 
37oC with 5% CO2. The MCF10A EGFR #7 and MCF10A EGFR #9 cell lines were a 
kind gift from Dr. Ben Ho Park (Johns Hopkins).  
MTT Assay 
MTT assay was performed with the CellTiter 96® Non-Radioactive Cell 
Proliferation assay (Promega) according to the manufacturer’s instruction. Treatments 
were done in triplicate. 
cAMP Measurements 
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The cAMP Complete ELISA Kit (Enzo Life Sciences) was utilized to measure 
cAMP levels in breast cancer cells according to the manufacturer’s instructions. 
Cell Cycle Analysis 
SKBR3 and MCF7 cell lines were grown to confluency in 100mm cell culture 
plates, then treated with DMSO or 1mM AICAR for a period of 24 or 48 hours. At the 
designated timepoint, cells were trypsinized with 0.25% Trypsin-EDTA and fixed with 
1:1 methanol:acetone. Fixed cells were stained with propidium iodide (Calbiochem) for 1 
hour. PI fluorescence of the samples was determined by FACSCalibur in the FL-3 
channel. 
Cell Viability Assay 
Cells were trypsinized and plated at a density of 2000 cells per well of a 6-well 
plate. Plates were treated, in triplicate, 24 hours later with increasing concentrations of 
AICAR, EGF or both. Cells were cultured 8-21 days under treatment, and then fixed with 
100% ethanol. After ethanol fixation, plates were stained with 0.5% crystal violet 
(Sigma). Cell viability was quantified by dissolving the crystal violet with 1% SDS and 
measuring absorbance with xMark™ Microplate Absorbance Spectrophotometer 
(BioRad) at 570nm. 
Western Blot Analysis 
For measurement of protein levels, cell lysate was collected in TNE lysis buffer. 
Protein concentration was determined by the Pierce BCA assay (Thermo Fisher 
Scientific). Protein from each sample was separated by SDS-PAGE on a 10% Tris-HCl 
gel (Bio-Rad). Protein was then transferred to a nitrocellulose membrane (Bio-Rad) and 
incubated overnight with the primary antibody. Most antibodies were incubated at a 
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1:1000 concentration, with the exception of anti-actin antibody (1:10,000). After 1 hour 
incubation with the anti-rabbit or anti-mouse secondary antibody, membranes were 
developed with SuperSignal West Femto Max Sensitivity Substrate (Thermo Fisher 
Scientific). For further analysis, membranes were stripped with Stripping Buffer (Thermo 
Fisher Scientific) and reprobed with subsequent primary antibodies.  
Constitutively Active and Dominant Negative AMPKα 
AMPKα Constitutively Active (CA) and Dominant Negative (DN) myc-tag 
labeled constructs in pcDNA3 (Invitrogen) plasmids were generously provided by Dr. 
David Carling (MRC Clinical Sciences Centre, Imperial College, London, UK). E. Coli 
DH5α was made competent via CaCl2 treatment then transformed with control (empty 
pcDNA3 vector), AMPKαCA or AMPKαDN plasmid. Transformed bacteria were grown 
under selection on ampicillin containing LB-agar plates. DNA was isolated from bacterial 
colonies using the PureLink® HiPure Plasmid Midiprep kit (Invitrogen). HCC1419 and 
SKBR3 cell lines were transfected in a 6-well plate with plasmid DNA using 
Lipofectamine® 2000 (Invitrogen). After 2 days, transfected cells were grown under 
150μg/ml G418 selection (Invitrogen). Cells were grown to confluency and cell lysate 
obtained. Western blot analysis was conducted to confirm the presence of AMPKαCA 
/AMPKαDN using myc-tag antibody (Cell Signaling Technology). 
Immunoprecipitation 
Cells were harvested in lysis buffer (50mM Tris, 150mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate) and supernatants incubated with rotation at 4oC with either anti-
HER2 or anti-EGFR antibody overnight. Protein G-Agarose (Roche Diagnostics) was 
added the next day, and lysates were placed on the rotator at 4oC for 4 hours. Protein G-
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agarose beads were isolated by centrifugation, washed three times with lysis buffer and 
heated for 5 minutes at 100oC in loading buffer. Samples were run on SDS-PAGE and 
then probed by immunoblot for HER2, AMPKα, and an antibody specific for 
phosphorylation of AMPK consensus site (anti-phospho-AMPK substrates). 
In vitro Kinase Assay 
AMPK (α1β1γ1) was purchased from SignalChem and assay conducted via 
manufacturer’s protocol with Kinase Dilution Buffer VII (SignalChem) and Kinase 
Assay Buffer I (SignalChem). [32P]-ATP was obtained from PerkinElmer. ATP and 
AMP were purchased from Sigma. In vitro AMPK inhibition was obtained with the 
addition of Compound C to the assay. Peptides were synthesized by the Johns Hopkins 
Synthesis and Sequencing Facility. Peptides synthesized were as follows: HA Peptide 
(NH2-YPYDVPDYA-OH), HER2#1 (NH2-TLERPKTLSPGRR-OH), HER2#2 (NH2-
SILRRRFTHQSDVRR-OH), HER2#2A (NH2-SILRRRFAHQSDVRR-OH), EGFR#1 
(NH2-FLQRYSSDPTGRR-OH), EGFR#2 (NH2-SILHRIYTHQSDVRR-OH), 
EGFR#2A (NH2-SILHRIYAHQSDVRR-OH). Peptides were tested in triplicate. 
Samples were blotted on P81 Whatman® Cellulose Paper (Sigma). Radioactivity was 
counted for the samples in the presence of scintillation fluid in a scintillation counter. 
Statistical Analysis  
Quantitative data were graphed and analyzed using GraphPad Prism 4 (GraphPad 
Software, La Jolla, CA). Error bars represent standard error unless mentioned. Student’s 
unpaired t tests were used for analysis of statistical differences. Differences were 
considered significant at p<0.05. 
28 
Chapter 3: AMPK Regulates HER2 and EGFR Activation 
3.1 Introduction 
As the critical sensor of cellular energy, AMP-activated Protein Kinase (AMPK) 
is considered the master metabolic regulator of the eukaryotic cell [68]. AMPK is 
activated in conditions that increase the cellular ADP:ATP or AMP:ATP ratio [82, 144, 
145]. Activation of AMPK has been reported to occur in response to exercise, ischemia, 
glucose deprivation, and genotoxic and oxidative stresses [144]. AMPK functions as a 
heterotrimer, composed of alpha, beta and gamma subunits [75]. AMP binds the gamma 
subunit of AMPK directly, which favors LKB1-mediated phosphorylation of AMPKα 
residue threonine 172 [144]. LKB1, the major upstream kinase of AMPK, is a known 
tumor suppressor [178]. As a serine-threonine kinase, AMPK is involved in a variety of 
cellular pathways [66, 75, 84, 87, 146, 147, 149, 152, 157, 158, 161, 163, 168, 169, 175, 
177]. Downstream targets of AMPK include: acetyl CoA carboxylase (ACC), raptor, 
HMG-CoA reductase, unc51-like autophagy activating kinase 1 (ULK1) and tuberin [67, 
145, 161]. Primarily, AMPK maintains energy homeostasis by turning on catabolic 
pathways that generate ATP, while switching off anabolic pathways that consume ATP 
[75]. AMPK is also reported to regulate mitochondrial biogenesis, autophagy, cell growth 
and proliferation, and regulate cell polarity [71, 160, 173].  
 Several studies have focused on AMPK as a potential target for cancer therapy. 
As AMPK couples energy status to growth, AMPK functions as a metabolic checkpoint 
[70]. Several oncogenic mutations and signaling pathways functionally bypass the 
AMPK-dependent metabolic checkpoint [71, 73, 182]. A study investigating AMPK 
activation levels in primary breast cancer determined AMPK activation was down-
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regulated in 90% of breast cancer patients [181]. Furthermore, the AMPK-upstream 
activating kinase LKB1 is known to be functionally inactive in ~20% non-small cell lung 
cancers [71]. Moreover, diabetic patients given metformin, an AMPK activating 
biguanide, were observed to have a lower incidence of breast cancer as compared to 
diabetic patients without metformin treatment [98, 100-105]. In the lab, metformin 
treatment has been determined to reduce tumor growth in xenograft, transgenic, and 
carcinogen-induced mouse cancer models [179, 180]. Furthermore, tumor-prone mice 
treated with three different AMPK activators (metformin, phenformin or A769662) 
displayed significantly delayed tumor development [144, 179].  
 In this section, we describe a novel interaction between AMPK and the HER2 and 
EGFR tyrosine protein kinases. We observed increased sensitivity of HER2 and EGFR 
overexpressing breast cancer cell lines to treatment with the AMPK activating agent 5-
Aminoimidazole-4-carboxamide ribonucleotide (AICAR). AICAR is converted to IMP, 
an analog of AMP, in the cell and thereby activates AMPK directly [93]. Our results 
suggest AMPK directly phosphorylates EGFR and HER2, leading to down-regulation of 
EGFR and HER2 activation and subsequently to tumor cell death. In this section, we 
describe a novel cell signaling interaction between HER2/EGFR and AMPK, which not 
only has biological relevance, but holds potential as a novel therapy strategy for the 
treatment of HER2 and EGFR expressing breast cancers. 
3.2 Results 
3.2.1 Activation of AMPK Decreases Breast Cancer Cell Viability 
 To determine what effects AMPK activation might have on proliferation and 
survival of breast cancer cells, we first screened a series of breast cancer cell lines for 
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survival after treatment with AICAR, the canonical activator of AMPK. As shown in 
Figure 1, we observed considerable variability in the sensitivity of breast cancer cell lines 
to AICAR treatment with a remarkable correlation between HER2-positive status and 
high sensitivity to AMPK activation. EGFR-expressing triple negative breast cancer cell 
lines appeared similarly sensitive, but breast cancer cell lines with low levels of both of 
these oncogenes showed relatively low sensitivity to AICAR. To confirm the results of 
our initial MTT assay screen for sensitivity, we conducted colony forming assays of 
breast cancer cell lines under continuous exposure to AICAR. As shown in Figures 2-4, 
breast cancer cell lines with high expression of HER2 and/or EGFR were again much 
more sensitive to AICAR treatment.  
To confirm the relationship between high HER2 or EGFR levels and sensitivity to 
AICAR, we tested MCF10A cells that were engineered by retroviral transduction to 
stably overexpress EGFR. Two independently EGFR overexpressing clones (MCF10A 
EGFR#7 and MCF10A EGFR #9) were compared to the parental MCF10A cell line 
using a colony forming assay to measure response to AICAR. As shown in Figure 5, 
MCF10A EGFR#7 cells and MCF10A EGFR#9 cells displayed increased sensitivity to 
AICAR treatment as compared to the parental MCF10A cell line, suggesting that EGFR 
overexpression increases sensitivity to AMPK-activating agents.  
In contrast to cells with high levels of HER2 or EGFR, MCF7, an ER-positive 
breast cancer cell line with negligible HER2 and EGFR expression, was relatively 
resistant to AICAR treatment (Figure 3). Comparing responses of MCF7 and SKBR3 to 
AICAR treatment by flow cytometry cell cycle analysis confirmed the greater sensitivity 
of the HER2-positive SKBR3 cells, with 49% of cells represented as sub-G1 fragments 
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after 24 hour treatment with 1mM AICAR (Figure 6). Noting the fragmentation of 
SKBR3 cells after treatment with AICAR, we sought to define apoptosis as a mechanism 
of cell death in these cells. We observed increased levels of cleaved PARP in SKBR3 
under AICAR treatment, which is consistent with apoptosis being the mechanism of cell 
death (Figure 8).  
3.2.2 AMPK activation reduces the level of HER2 and EGFR autophosphorylation  
 Given that high expression of HER2 and EGFR in breast cancer cell lines 
correlates to increased sensitivity to AMPK activation, we sought to determine the 
connection between AMPK activation and the EGFR/HER2 pathway. To test whether 
AICAR’s anti-growth effect is mediated by limiting HER2 and EGFR signaling, we 
assessed the effect of AMPK activation on the main activating autophosphorylation sites 
of HER2 and EGFR. As shown in Figures 13 and 14, AMPK activation results in 
diminished HER2 and EGFR activating phosphorylation. Furthermore, extended 
treatment of AICAR on EGFR-overexpressing cell lines results in decreased levels of 
total EGFR protein (Figures 15 and 16).  
3.2.3 Genetic studies confirm the role of AMPK in the regulation of HER2 and 
EGFR activation 
 To confirm that the inhibitory effect of AICAR on HER2 and EGFR 
phosphorylation is mediated by AMPK, we transfected SKBR3 cells with AMPK siRNA. 
As a heterotrimer, functional AMPK is composed of α, β, and γ subunits; we found that 
AMPK β siRNA was more efficacious than AMPK α in the knockdown of AMPK 
protein (Figure 17). Under conditions of AMPK knockdown (using AMPK β siRNA), we 
observed increased activating phosphorylation of EGFR and HER2 (Figures 17 and 18). 
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In additional experiments, transfection of HCC1419 and SKBR3 cells with AMPKα 
constitutively active (CA) and dominant negative (DN) Myc-tag labeled constructs 
further validated the regulatory role of AMPK on HER2 and EGFR. Myc-tag expressing 
clones were isolated under G418 antibiotic selection and analyzed for HER2 and EGFR 
phosphorylation status (Figures 19-21). Similar to the effect of AICAR treatment, AMPK 
CA clones demonstrated decreased phosphorylation of HER2 and EGFR (Figures 19-21). 
Taken together, these results strongly support the notion of AMPK mediating an 
inhibitory effect on HER2 and EGFR activation. 
3.2.4 EGFR ligands rescue breast cancer cells from AMPK-based cytotoxicity 
 To determine whether AMPK-mediated inhibition of HER2 and EGFR is 
responsible for the cytotoxic effects in HER2/EGFR overexpressing cell lines, we 
assessed whether stimulation of the EGFR/HER2 pathway would have a rescue effect. As 
shown in Figures 22 and 23, concurrent treatment of HER2-positive breast cancer cells 
with AICAR and EGF resulted in a rescue effect. When compared to AICAR treatment 
alone, concurrent AICAR and EGF treatment result in a 31% rescue of colony forming 
efficiency in HCC1419 (Figure 22). These results suggest the cytotoxic effects of AMPK 
activation are mediated mainly through inhibition of HER2/EGFR signaling. By 
stimulating HER2/EGFR signaling through EGF treatment, AMPK-mediated inhibition 
of HER2/EGFR is counterbalanced, resulting in a rescue of cell viability. 
3.2.5 AMPK directly binds HER2 and phosphorylates HER2 and EGFR 
 Given that our results suggest AMPK-dependent regulation of HER2/EGFR 
activation, we next set out to determine whether AMPK regulation of HER2/EGFR is a 
result of a direct interaction (Figure 27) of AMPK with these receptor tyrosine kinase 
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proteins. Our analysis of HER2 and EGFR amino acid sequences revealed that each 
protein has two sequences that potentially fit the AMPK substrate consensus motif 
(Figure 24), which is LXRXX(S/T), where X represents any amino acid. Using an 
antibody that recognizes the phosphorylated LXRXX(S/T) motif (Phospho-
(Serine/Threonine) AMPK Substrate), we immunoprecipitated HER2 and EGFR and then 
probed the precipitated proteins with the phospho-(S/T) AMPK substrate sequence. 
These experiments revealed that both EGFR and HER2 harbor the AMPK substrate motif 
(Figure 25). Furthermore, the presence of the phosphorylated LXRXX(S/T) motif 
increased with treatment of AICAR, indicating that AMPK directly phosphorylates 
HER2/EGFR (Figure 25).  We also performed co-immunoprecipitation experiments to 
determine if AMPK directly interacts with HER2/EGFR, and as shown in Figure 26, 
AMPK co-immunoprecipitates with HER2. These results confirm that AMPK negatively 
affects EGFR and HER2 activation through a direct interaction.  
3.2.6 AMPK in vitro kinase assay reveals phosphorylation sites on HER2 and EGFR 
for AMPK 
 To determine which of the two possible phosphorylation sequences on HER2 and 
EGFR represented the site of AMPK phosphorylation, we designed an in vitro kinase 
assay experiment. We synthesized four peptides corresponding to the potential 
phophorylation sites, which we designate as HER2a, HER2b, EGFRa, and EGFRb 
(Figure 28). Based on the results of the in vitro assay, we determined that HER2b and 
EGFRb correspond to the specific sites of AMPK phosphorylation (Figure 29). To 
validate these sites of AMPK phosphorylation, we synthesized two additional peptides 
based on the sequence of HER2b and EGFRb, wherein the prospective phosphorylated 
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(Figure 28). The 
inability of AMPK to phosphorylate these altered peptides confirmed that HER2 
threonine 900 and EGFR threonine 892 are specific phosphorylation sites for AMPK. 
These results also provide additional confirmation that AMPK inhibits HER2 and EGFR 
activity through a direct phosphorylation event. Moreover, our discovery of AMPK-
mediated regulation of HER2/EGFR signaling provides an explanation for the heightened 
sensitivity observed in HER2/EGFR overexpressing breast cancer cell lines to the AMPK 
activating agent, AICAR. 
3.3 Discussion 
 In summary, this series of experiments demonstrate that activated AMPK 
preferentially inhibits the growth of HER2/EGFR-dependent breast cancer cells. AMPK 
has several downstream targets and is a key player in regulating cell growth and 
metabolism processes. We show that AMPK activation results in cell growth inhibition 
through the disruption of HER2/EGFR signaling. AMPK activation negatively regulates 
HER2/EGFR signaling, which has a direct, negative impact on breast cancer cell 
survival. Our results suggest that AMPK activating agents may have therapeutic benefit 
for HER2/EGFR-dependent breast cancers. 
EGFR and HER2, of the ErBb family of tyrosine protein kinases, are implicated 
in driving several important types of human cancers. EGFR is overexpressed in some 
breast, bladder, kidney, non-small lung, and prostate cancers [42, 49, 50], whereas HER2 
is overexpressed in breast, colon, endometrial, lung, cervix, esophageal and pancreatic 
cancers [184]. To mediate cell growth and proliferation, EGFR and HER2 must be 
activated through a multi-step process that involves ligand binding, homo- or 
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heterodimerization, and autophosphorylation of key tyrosine residues in the intracellular 
domain [185]. When activated, both HER2 and EGFR drive cell growth through 
downstream signaling pathways [184]. MAPK and Akt pathways, two such downstream 
pathways, are especially well-studied for their role in cancer biology [186]. The 
importance of EGFR and HER2 signaling is evidenced by the surfeit of overexpression or 
activating mutations of these proteins in cancer [184, 187]. HER2 is overexpressed in 
~25% of breast cancer and as many as 15% of breast cancers overexpress EGFR [184, 
188]. Furthermore, co-overexpression of HER2 and EGFR has been linked to poor 
clinical outcome in breast cancer patients [187].  
Being key players in cancer development and growth, HER2 and EGFR have 
emerged as attractive targets for pharmacological intervention [49, 61]. Currently, both 
immunological and pharmacological inhibition strategies are practiced in the clinic. 
Trastuzumab, a humanized monoclonal antibody to HER2, is currently utilized in the 
treatment of HER2 overexpressing breast cancer and effectively down-regulates surface 
HER2 [50-53]. Lapatinib, a small molecule dual inhibitor of EGFR and HER2, is also a 
current therapy option for HER2-positive breast cancer patients [41, 58, 188], although as 
monotherapy, lapatinib has limited benefit, with a 4.3% response rate in patients with 
HER2-positive breast cancer [186, 189, 190]. While these therapies have proven 
efficacious in the treatment of HER2 overexpressing breast cancer, not all HER2-positive 
cancers respond to these treatments and the development of trastuzumab and lapatinib 
resistance is a growing issue of concern [191]. Moreover, triple negative breast cancer 
(TNBC) remains difficult to treat, with a high risk of metastasis and disease recurrence 
[192]. TNBC is a broad term that encompasses a heterogeneous group of breast cancers 
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that are defined by their lack of estrogen receptor (ER), progesterone receptor (PR) and 
HER2 expression [193]. TNBC is usually characterized as aggressive tumors with 
systemic treatment options limited to cytotoxic chemotherapy [39]. Approximately 30-
50% of TNBC overexpress EGFR [194]. The high frequency of EGFR overexpression in 
TNBC would support the use of EGFR inhibitors as a strategy in TNBC treatment [195]. 
Although anti-EGFR therapy is expected to be efficacious for TNBC treatment, clinical 
trials have thus far shown no clinical benefit for a variety of anti-EGFR therapies [195]. 
Consequently, the development of novel therapies is of vital import for the treatment of 
TNBC. 
 Although much is known about EGFR and HER2 activation and subsequent 
signaling pathways, little is known about the regulation of EGFR and HER2 under 
conditions of metabolic stress. Conditions of metabolic or environmental stress would not 
only be a detriment to the cell, but logically would inhibit cell growth signaling 
pathways. While several proteins are involved in conveying cellular stress response, 
AMP-activated protein kinase (AMPK) is known as the master metabolic regulator of the 
cell for its varied functions in regulating lipid, carbohydrate and protein synthesis [67].  
 In this section, we explored the connection between HER2/EGFR-dependent cell 
signaling and sensitivity to AMPK activation. Subsequently, we determined a novel 
regulation-based interaction between AMPK and HER2/EGFR. Specifically, activated 
AMPK directly binds HER2 and phosphorylates HER2 at threonine 900. Similarly, 
AMPK recognizes a consensus sequence on EGFR and phosphorylates at threonine 892. 
Our findings clearly define a novel signaling pathway, whereby AMPK regulates 
HER2/EGFR activity through direct inhibitory phosphorylation. These results not only 
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provide a mechanism for efficacy of AMPK agonists in HER2/EGFR-activated breast 
cancer, but also support the therapeutic use of AMPK agonists in the treatment of HER2 






Figure 1: AICAR reduces the survival of HER2-amplified breast cancer cell lines. 
MTT assay analysis of breast cancer cell line viability with DMSO control, 0.5mM and 
1mM AICAR treatment. Breast cancer cell lines were seeded into a 96-well plate and 
treated for 24 hours. Treatments were done in triplicates and results were measured using 







Figure 2: Analysis of HER2 and EGFR levels in selected breast cancer cell lines. 
Western blot analysis of HER2 and EGFR levels in selected breast cancer cell lines, 
showing that the cell lines with greatest sensitivity to AICAR have relatively high levels 







Figure 3: Sensitivity profiles of ER+ and HER2+ breast cancer cell lines to 
continuous AMPK activation. Clonogenicity (colony forming efficiency) of MCF7 and 
SKBR3 cells treated with indicated concentrations of AICAR. Colony forming assays 







Figure 4: Cell growth inhibition in triple negative breast cancer cell lines exposed to 
continuous AMPK activation. Clonogenicity of MDA231 and HCC1806 cells – two 
cell lines with high levels of EGFR expression – treated with the indicated concentrations 
of AICAR. Cells were treated for 2 weeks then fixed and stained. Colony forming assays 







Figure 5: EGFR overexpression in the MCF10A cell line increases sensitivity to 
AICAR treatment. Clonogenicity of MCF10A empty vector (pFBneo) cells and 
MCF10A clones with stable overexpression of EGFR (EGFR #7 and EGFR #9) treated 
with AICAR.  Overexpression of EGFR in MCF10A cells results in increased sensitivity 







Figure 6: Cell cycle analysis of MCF7 and SKBR3 cells under 24 hour AICAR 
treatment. Flow cytometry measurements of cell-cycle distribution of propidium iodide-
stained SKBR3 and MCF7 cells treated for 24 hours with either 1mM AICAR or DMSO 
only. Presence of large sub-G1 populations in AICAR-treated SKBR3 cells suggests 








Figure 7: Cell cycle analysis of MCF7 and SKBR3 cells under 48 hour AICAR 
treatment. Flow cytometry measurements of cell-cycle distribution of propidium iodide-
stained SKBR3 and MCF7 cells treated with either DMSO or 1mM AICAR for 48 hours. 






Figure 8: AICAR treatment causes apoptotic cell death in SKBR3 cells. Western blot 
analysis for cleaved PARP in SKBR3 treated for 24 hours with indicated concentrations 







Figure 9: AICAR treatment activates AMPK in breast cancer cell lines. (A) Western 
blot analysis of MCF7 treated with either 1mM AICAR or (control) for 24 hours. 
Phosphorylation of AMPK at threonine 172 indicates activation of AMPK. AMPK-
mediated phosphorylation of Acetyl Co-A Carboxylase (ACC) at serine 79 confirms 
AMPK activation. (B) Western blot analysis of SKBR3 treated for 24 hours with DMSO 










Figure 10: AICAR treatment activates AMPK in HER2+ breast cancer cell lines. 
Western blot analysis of 24 hour AICAR treatment in the HER2 positive cell lines BT474 











Figure 11: AICAR treatment activates AMPK in triple negative breast cancer cell 
lines. Western blot analysis of triple negative breast cancer cell lines HCC1806 (A) and 










Figure 12: AICAR treatment activates AMPK in the EGFR overexpressing cell lines 
MCF10A #7 and #9. Western blot analysis of MCF10A and the EGFR overexpressing 
clones MCF10A #7 EGFR (A and B) and MCF10A #9 EGFR (B) for activation of 










Figure 13: AMPK activation leads to decreased levels of HER2 and EGFR 
phosphorylation. (A) Western blot analysis shows decreased levels of phosphorylated 
HER2 and EGFR in SKBR3 cells treated for 24 hours with indicated concentrations of 
AICAR compared to DMSO control. (B) Similarly, further Western blot analysis of both 











Figure 14: AMPK activation leads to decreased levels of phosphorylated HER2, 
HER3, and EGFR in HER2+ breast cancer cell lines. (A) Western blot analysis of 
phosphorylated HER3, HER2, and EGFR protein in HCC1419 treated with either DMSO 
or 1mM AICAR for 96 hours. (B) Western blot analysis of phosphorylated levels of 








Figure 15: AMPK activation leads to decreased EGFR activation. (A-C) Western blot 
analysis of the phosphorylated and total level of EGFR protein in MCF10A #7 and #9 











Figure 16: AMPK activation inhibits EGFR activation in triple negative breast 
cancer. Western blot analysis of phosphorylated and total EGFR levels in MDA231 with 






Figure 17: Regulatory role of AMPK in HER2 and EGFR activation is confirmed by 
genetically regulating AMPK levels and activity. SKBR3 cells were transfected with 
AMPKα1/2, AMPKβ1, AMPKβ2, or scrambled control siRNA and three days after 
transfection, cell lysates were evaluated by immunoblot for HER2, p-HER2(1248)/p-
EGFR(1173), EGFR, p-AMPKα(172), AMPKα, AMPKβ1/2, and p-HER2(1221-2). Note 
increased levels of p-HER2 (1248)/p-EGFR (1173) and p-HER2 (1221-2) with AMPKβ1 
or AMPKβ2 knockdown, while levels of AMPKα and AMPKβ are decreased by 






Figure 18: Knockdown of AMPK affects EGFR activation in triple negative breast 
cancer. HCC1806 cells were transfected with AMPKβ1, AMPKβ2, or scrambled control 
siRNA and three days after transfection, cell lysates were evaluated by immunoblot for p-
EGFR (1142), p-EGFR (1068), EGFR, actin, AMPKα, and AMPKβ1/2. Note increased 
levels of p-EGFR (1068) and p-EGFR (1142) levels with AMPKβ2 knockdown, while 






Figure 19: Regulatory role of AMPK in HER2 and EGFR activation is confirmed 
with AMPK Constitutively Active (CA) and Dominant Negative (DN) constructs in 
SKBR3. SKBR3 cells transfected with constitutively active (CA) AMPKα show 
decreased phosphorylation of HER2 (1248 and 1196) and EGFR (1173), whereas cells 
transfected with dominant negative (DN) AMPKα show increased phosphorylation of 






Figure 20: Regulatory role of AMPK in HER2 and EGFR activation is confirmed 
with AMPK Constitutively Active (CA) and Dominant Negative (DN) constructs in 
HCC1419. HCC1419 cells transfected with constitutively active (CA) AMPKα show 







Figure 21: Constitutively Active AMPK regulates EGFR phosphorylation. In the 
HER2 positive breast cancer cell lines, HCC1419 and SKBR3, expression of a 
Constitutively Active AMPK construct negatively regulates the EGFR activating 
phosphorylation site (1068). Presence of a myc-tag protein indicates presence of the 







Figure 22: EGF treatment rescues AICAR-mediated growth inhibition in HCC1419 
breast cancer. To test the importance of HER2/EGFR signaling in cell survival, we 
activated EGFR signaling with EGF ligand in the HCC1419 cell line. HCC1419 cells 
were treated with designated concentrations of AICAR and EGF. Experiments were 
conducted in triplicates. After two weeks, plates were stained with crystal violet. Staining 
was quantified by spectrophotometer-based absorbance analysis. Percentages shown 








Figure 23: EGF treatment rescues AICAR-mediated growth inhibition in BT474 
breast cancer. To test the importance of HER2/EGFR signaling in cell survival, we 
activated EGFR signaling with EGF ligand in the BT474 cell line. BT474 cells were 
treated with designated concentrations of AICAR and EGF. Experiments were conducted 









Figure 24: Identification of an AMPK substrate consensus sequence on HER2.  
































Figure 25: Activated AMPK phosphorylates an AMPK consensus site on HER2 and 
EGFR. Lysates of HCC1419 (A) and HCC1806 (B) cells treated with DMSO or AICAR 
for 24 hours were immunoprecipitated with anti-HER2 (HCC1419) or anti-EGFR 
(HCC1806) and probed with an antibody specific for phosphorylation of the AMPK 
consensus sequence (LXRXX(p-S/T)). Note increased phosphorylation of this AMPK 




















Figure 26: AMPK co-immunoprecipitates with HER2 in HER2-amplified breast 
cancer. HCC1419 (A), BT474 (B), and SKBR3 (B-C) cell lines were 
immunoprecipitated with anti-HER2. Western blot of HER2-immunoprecipitated lysates 



















Figure 28: Identification of potential AMPK phosphorylation sites on HER2 and 
EGFR. HER2 and EGFR amino acid sequences were analyzed for the AMPK substrate 
consensus sequence. We determined two potential phosphorylation sites per protein, 
designated HER2a, HER2b, EGFRa, and EGFRb. Mutant peptides (HER2b
TA, 
EGFR2b
TA) were synthesized, where the proposed site of AMPK phosphorylation was 
changed to an alanine. These peptide sequences of HER2 and EGFR were utilized in the 







Figure 29: Activated AMPK phosphorylates an AMPK consensus site on HER2 and 
EGFR. (A) In vitro AMPK kinase assay using HER2 peptides (performed in triplicate) 
show AMPK-dependent phosphorylation of a specific HER2 sequence (HER2b, p < 
0.0002). HA peptide was used as a negative control, Compound C was used as inhibitor 
of AMPK kinase activity, and a variant form (HER2b
T→A
) of the peptide was used to 
demonstrate specificity of the phosphorylation site. (B) In vitro AMPK kinase assay 
using EGFR peptides (performed in triplicate) similarly shows AMPK-dependent 
phosphorylation of specific EGFR sequence (EGFRb, p < 0.0001).  As above, compound 
C inhibits AMPK kinase activity, and a variant form (EGFRb
T→A
) of the peptide, was 





Chapter 4: AMPK is activated in Breast Cancer Cells by other 
Compounds, including Morin, a Natural Flavonoid 
4.1 Introduction 
AMPK activity regulates protein synthesis, glucose metabolism, and fatty acid 
synthesis [75, 84, 144, 146, 149, 168]. As such, AMPK activity must be tightly regulated 
during carcinogenesis. AMPK activity has been found to be downregulated in primary 
breast cancer [181]. Recently, attention has been brought to the use of AMPK agonists in 
the treatment of cancer [69, 179, 181]. AMPK, as the master metabolic regulator of the 
cell, is an attractive target in the treatment of the highly metabolic condition of cancer 
[67, 69, 164, 170]. Although pharmacological activation of AMPK has been reported to 
induce apoptosis and/or inhibit the growth of cancer in both in vitro and in vivo settings, 
the main pathways downstream of AMPK that mediate this anti-cancer activity remains 
to be conclusively defined [67, 70, 149, 161, 163]. The matter is further complicated by 
both the wide variety of compounds that activate AMPK, and the differing means of 
AMPK activation [69, 83, 90, 107, 113-116, 119, 141, 142, 150, 179]. 
In this section, we utilize pharmacological manipulation of AMPK to determine 
the differences and similarities in the mechanism of action of AMPK in breast cancer. 
First, we tested metformin, a biguanide used in the treatment of diabetes, that is known to 
activate AMPK in hepatocytes [101, 102, 104, 105, 141]. Metformin directly inhibits 
complex I of the respiratory chain, which affects the AMP:ATP ratio, which subsequently 
activates AMPK [95, 141]. Subsequently, we tested morin, a flavonoid, which was 
previously determined to inhibit fatty acid synthase (FASN) in vitro [137]. Additional 
studies attribute morin with diverse functions, including anti-tumorigenic activity [121-
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123, 128, 129, 131, 135]. As AMPK activation is tied to inhibition of fatty acid synthase 
activity, and previous reports determined a variety of flavonoids can activate AMPK, we 
sought to determine if morin activates AMPK in breast cancer [22, 116, 119, 120]. C75, a 
synthetic FASN inhibitor, was shown to have anti-tumorigenic activity in breast cancer 
[24, 196]. As both morin and C75 are reported to inhibit FASN, we sought to determine 
if the two compounds have similar effects on the AMPK pathway. 2-Deoxy-D-glucose 
(2DG) is an analog of glucose that cannot be utilized to produce energy [197]. 2DG is 
known to activate AMPK by compromising the efficiency of energy produced through 
glucose metabolism [197, 198]. Through the use of several different AMPK activating 
compounds, we have attempted to clarify the mechanism behind AMPK-mediated anti-
tumorigenic activity in breast cancer. 
4.2 Results 
4.2.1 AMPK-activating compounds decrease HER2+ breast cancer viability 
 An initial screen of AMPK-activating compounds on HER2+ breast cancer 
exhibited a range of results (Figure 30). HER2+ breast cancers demonstrated sensitivity 
to all AMPK-activating agents, although the concentration of the pharmacological agents 
varied from 100μM to 3mM. Compared to SKBR3, HCC1419 breast cancer cells 
displayed greater sensitivity to 2DG, which indicates a greater dependence on glucose 
metabolism in HCC1419 cells (Figure 30). Inhibition of cell viability by metformin was 
highly time dependent, as a 24 hour treatment resulted in a 20-40% decrease in cell 
viability, while a 72 hour treatment had a 40-60% decrease in cell viability (Figure 30). 
AICAR, the canonical activator of AMPK, was more effective in decreasing cell viability 
than either 2DG or metformin treatment (Figure 30). A 72 hour 1mM AICAR treatment 
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resulted in a 70-80% decrease in cell viability in HER2+ breast cancer. Morin treatment 
highly depended on concentration. The 100μM morin treatment hardly had any effect on 
cell viability, while the 200μM morin treatment had a profound effect on cell viability 
(Figure 30).  
 Colony forming assays of morin treatment in the HER2+ breast cancers SKBR3 
and HCC1419, the EGFR+ breast cancers BT549 and MDA231, and the ER+ breast 
cancer MCF7, demonstrated a greater sensitivity to morin treatment in HER2+ and 
EGFR+ breast cancer (Figures 31-33). Treatment of HER2+ and EGFR+ breast cancers 
with 200μM morin greatly affected cell growth, while 200μM morin treatment in MCF7 
barely affected cell growth (Figures 31-33).  
 Metformin treatment in EGFR+ breast cancer displayed results similar to morin 
(Figure 34). BT549 was sensitive to metformin at concentrations lower than MCF7. A 
treatment of 10mM metformin was necessary to prevent cell growth in MCF7, while 
3mM treatment was sufficient to prevent growth of BT549 (Figure 34). 
4.2.2 Metformin and morin treatment activate AMPK in breast cancer cell lines 
 Although metformin activates AMPK, its direct target is the mitochondrial 
complex I of the respiratory chain [95, 141]. By inhibiting the mitochondrial respiratory 
chain, metformin causes a drop in the rate of ATP synthesis [199]. Metformin’s indirect 
activity on AMPK activation may explain its lower effectiveness in inhibiting cancer cell 
growth. Activated AMPK, shown by phosphorylation of the AMPKα site threonine 172, 
is observed after metformin treatment for 96 hours in breast cancer (Figure 35).  
 Contrastingly, 24 hour treatment with either 100μM or 200μM morin 
demonstrates a clear activation of AMPK in HER2+ breast cancer (Figure 36). Activation 
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of AMPK by morin is comparable to AICAR treatment (Figure 36). As morin was 
previously reported to be a potent inhibitor of FASN in vitro, we sought to determine if 
morin’s affect on AMPK was related to inhibition of FASN [137]. However, treatment of 
BT474 with C75, a synthetic FASN inhibitor, did not activate AMPK (Figure 37). As 
C75-mediated inhibition of FASN did not activate AMPK, we determined that morin-
induced activation of AMPK must occur separately from FASN inhibition.  
4.2.3 Metformin and morin treatment inhibit the activation of EGFR in HER2+ 
breast cancer 
 Preliminary experiments looking at the effect of metformin treatment on HER2+ 
breast cancer demonstrate results similar to the effect of AICAR. Metformin treatment 
inhibited activation of EGFR in HER2+ breast cancer (Figure 38). Furthermore, morin 
treatment also displayed inhibitory effects on EGFR phosphorylation (Figure 39). 
Analysis of morin treatment on MAPK pathways revealed no effect on ERK1/2 
phosphorylation; however, phosphorylation of RSK appeared to increase (Figure 40). 
Further investigation appears necessary to elucidate the exact impact of morin treatment 
on breast cancer. Interestingly, both metformin and C75 treatment inhibit mTOR 
phosphorylation, which might play a role in mediating the anti-tumor effects of these 
agents (Figure 41). 
4.2.4 Morin and the level of cAMP in breast cancer 
Previous studies have documented an existing relationship between cyclic 
adenosine monophosphate (cAMP) and adenosine monophosphate-activated protein 
kinase (AMPK). Although the scientific community appears unresolved as to the exact 
nature of this association between cAMP and AMPK, the general consensus provides that 
72 
an increase in cAMP levels leads to an early transient activation of AMPK. Prior studies 
also document a feedback mechanism that is responsible for inhibition of AMPK activity 
under conditions of continually elevated cAMP levels.   
In the article “Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by 
Inhibiting cAMP Phosphodiesterases,” the authors examine the interaction of the cAMP 
and AMPK pathways in C2C12 myotubes treated with resveratrol [112]. Treatment of 
mice with resveratrol, a polyphenol, is reported to delay aging-related phenotypes [112]. 
The beneficial effects of resveratrol on aging-related conditions are linked to the proteins 
sirtuin 1 (Sirt1) and sirtuin 2 (Sirt2) [109, 110, 171]. According to Park SJ, et al., 
resveratrol treatment causes an increase in cAMP levels through the inhibition of 
phosphodiesterases [112]. Intracellular levels of cAMP depend on two classes of 
proteins: adenylate cyclase and phosphodiesterases [112]. Adenylate cyclase synthesizes 
cAMP from ATP while phosphodiesterases hydrolyze cAMP to AMP [112]. By 
inhibiting phosphodiesterase, resveratrol prevents the breakdown of cAMP to AMP 
[112]. The subsequent increase in cAMP levels activates the cAMP-regulated guanine 
nucleotide exchange factors (cAMP GEFs) Epac1 and Epac2 [112]. Epac1 is required for 
resveratrol-mediated activation of AMPK. Epac1 activates AMPK indirectly by 
increasing intracellular Ca
2+
 levels, leading to the activation of calcium/calmodulin-
dependent kinase kinase β (CamKKβ), a known AMPK kinase [200-203]. 
We have shown that morin, a flavonoid, also activates AMPK in cell culture 
conditions. However, the mechanism behind morin-mediated activation of AMPK 
remains undetermined. To ascertain whether morin activates AMPK through modulation 
of cAMP levels, we measured cAMP levels in breast cancer cell cultures under treatment 
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conditions (Figures 42 and 43). Based on the results, it appears that cAMP levels 
fluctuate within the cell regardless of treatment (Figures 42 and 43). For BT474, a 
HER2+, ER+ breast cancer cell line with a PIK3CA mutation, a 24 hour AICAR 
treatment slightly increased cAMP levels. In HCC1419, 24 hour treatment of 2-deoxy-D-
glucose or morin caused an increase in cAMP levels. A 2 hour treatment of 2,5 
dideoxyadenosine (adenylate cyclase inhibitor) or lapatinib (HER2/EGFR inhibitor) also 
effectively increase levels of cAMP. Contrastingly, a 2 hour treatment of HCC1419 with 
EGF decreases overall cAMP levels. A 24 hour treatment of HCC1419 with 500μM 
AICAR increases cAMP levels slightly, while a 24 hour treatment of 1mM AICAR 
decreases cAMP levels. As cAMP is a second messenger, its role within the cell is 
transient. Due to the large variability in cAMP levels, we cannot conclusively state that 
AMPK activation occurs through inhibition of phosphodiesterases in morin-treated cells. 
Future studies that focus on correlating morin-based activation of AMPK with the 
inhibition of phosphodiesterases should also measure the level of intracellular Ca
2+
 and 
activation of CamKKβ. 
4.3 Discussion 
 In summary, we have shown that AMPK activating agents preferentially inhibit 
the growth of HER2+ breast cancer. Metformin, a biguanide currently used in the clinic 
to treat diabetes, required extended treatment time points to activate AMPK. Metformin 
activates AMPK indirectly, which may explain the amount of time required for AMPK 
activation. Morin, a flavonoid, has been attributed with many functions. Morin is reported 
to inhibit fatty acid synthase (FASN), inhibit nuclear factor kappa-light-chain-enhancer 
of activated B cells (NFκB), and the inflammatory response [122, 124, 131, 137]. Here, 
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we describe a novel function for morin in the activation of AMPK. Contrastingly, C75, a 
known FASN inhibitor, does not activate AMPK, indicating that morin activity on 
AMPK cannot be attributed to FASN inhibition. Correspondingly, lack of C75-based 
activation of AMPK has been observed in prior published articles [204]. Furthermore, 
similar to AICAR activity, both metformin and morin have inhibitory effects on EGFR 
activation. We propose the enhanced sensitivity of HER2+ breast cancers to AMPK-
activating agents is through AMPK-mediated inhibition of the ErbB family of growth 
factor receptors. 
 HER2+ breast cancer is highly dependent on HER2/EGFR signaling. In this 
study, we describe a novel mechanism wherein AMPK directly mediates an inhibitory 
effect on HER2 and EGFR signaling. While several studies have focused on uncovering 
AMPK substrates, HER2 and EGFR represent previously unstudied substrates of AMPK. 
In Banko et al., the use of HEK293T cells in their screen for AMPK substrates 
overlooked HER2 and EGFR because HEK293T cells do not express either HER2 or 
EGFR [205-207]. By using the pharmacological agents- metformin, AICAR, and morin, 
we demonstrate that inhibition of HER2/EGFR is through AMPK activation. Although 
the mechanism of AMPK activation through morin is currently unknown, we hypothesize 
morin activation of AMPK occurs in a mechanism that differs from resveratrol. Morin 
does not seem to have inhibitory activity on phosphodiesterases [112]. We propose the 
use of AMPK activating agents would be useful in the clinic for therapy of HER2 or 
EGFR-dependent cancers. Several types of cancer are dependent on either EGFR or 
HER2 signaling. HER2 signaling is important, not only in breast cancer, but also colon, 
ovarian, endometrial, lung, uterine cervix, head and neck, gastric and esophageal 
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carcinomas [41, 42, 49, 186]. EGFR signaling is equally important and found in a variety 
of cancer types including: breast, lung, glioblastoma, and squamous cell carcinomas [56, 
61-65, 187]. Our results support the development of potent, clinically relevant AMPK 

















Figure 30: AMPK-activating agents reduce the survival of HER2-amplified breast 
cancer cell lines. MTT assay analysis of breast cancer cell line viability with DMSO 
control, 1mM and 3mM 2DG, 1mM and 3mM metformin, 0.5mM and 1mM AICAR, and 
100μM and 200μM morin treatment. Breast cancer cell lines were seeded into a 96-well 
plate and treated for either 24 or 72 hours. Treatments were done in triplicates and results 
were measured using a spectrophotometer at 570nm with a reference wavelength of 






















Figure 31: Cell growth inhibition in HER2+ breast cancer cell lines treated with 
morin. Clonogenicity of HCC1419 (A) and SKBR3 (B) cells with treatment of the 
indicated amounts of morin. Cells were treated for 2 weeks then fixed and stained. 












Figure 32: Cell growth inhibition in EGFR+ breast cancer cell lines treated with 
morin. Clonogenicity of BT549 (A) and MDA231 (B) cells with treatment of the 
indicated amounts of morin. Cells were treated for 2 weeks then fixed and stained. 








Figure 33: Morin treatment in ER+ breast cancer does not affect cell viability. 
Clonogenicity of MCF7 cells with treatment of the indicated amounts of morin. Cells 











Figure 34: EGFR-dependent cell line, BT549, displays heightened sensitivity to 
metformin treatment. BT549 (A) and MCF7 (B) were treated with the indicated 
concentrations of metformin. Treatments were performed in triplicates. Note the higher 














Figure 35: Metformin treatment activates AMPK in HER2+ breast cancer. Western 
blot analysis of 96 hour metformin treatment in the MCF10A (A), and the HER2 positive 


































Figure 36: Morin treatment activates AMPK in HER2+ breast cancer. Western blot 
analysis of 24 hour metformin treatment in HCC1419 (A), and time course based 
treatments of morin in BT474 (B), SKBR3 (C), and HCC1410 (D). Note how morin 
treatment activates AMPK in levels comparable to AICAR in HCC1419. The letter C 







Figure 37: Inhibition of FASN does not activate AMPK. BT474 breast cancer cells 
were treated for 24 hours with the indicated concentrations of agents. Note that C75 













Figure 38: Metformin treatment inhibits EGFR activation. BT474 and SKBR3 cells 
were treated with either control or 3mM metformin for 96 hours. In HER2+ breast 









Figure 39: Morin treatment inhibits EGFR activation in HER2+ breast cancer. 
HCC1419 (A) and SKBR3 (B) were treated with 200μM morin for the indicated time 








Figure 40: Morin does not inhibit ERK1/2 signaling. HCC1419 treated with 200μM 
morin for the indicated time points. The letter C represents control DMSO treatment at 96 
hours. Note p-ERK1/2 levels remain stable; however, levels of p-RSK appear to increase. 
Given that RSK phosphorylation is directly downstream of ERK, the cause of the above 









Figure 41: Treatment of metformin or C75 inhibit mTOR activation. BT474 and 
SKBR3 cells (A) were treated for 96 hours with 3mM metformin. BT474 (B) was treated 
for 24 hours with the indicated concentrations of the FASN inhibitor, C75. Levels of p-








Figure 42: Measurement of cAMP levels in BT474 following pharmacological 
treatment. BT474 was treated for 24 hours with the following: DMSO (control), 
Compound C, AICAR, metformin, morin or 2DG at the indicated concentrations. Results 
are shown as pmol cAMP/mg protein. Note that in the first course of treatments, 
Compound C, an AMPK inhibitor, and AICAR caused a slight increase in the levels of 
cAMP. In the second course of treatments, none of the pharmacological agents increased 







Figure 43: cAMP measurement in HCC1419 breast cancer cells following 
pharmacological treatment. HCC1419 cells were either treated for 2 or 24 hours. The 2 
hour treatments involved: 2,5, dideoxyadenosine, EGF or lapatinib. The 24 hour 
treatments included: 2-deoxy-D-glucose, AICAR, and morin. Results are shown as pmol 
cAMP/mg protein. Note the large variation in cAMP levels, regardless of treatment. 
Further investigation into this area is required for conclusive results.
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